Novo Nordisk’s Medicare Bridge Mixes Clinical Muscle with a Buyback Boost
Published on 06/30/2026 at 08:31 | Redaktion boerse-global.de
The Medicare GLP-1 Bridge program that opens on July 1, 2026, hands Novo Nordisk a potential turning point for its Wegovy franchise, but the Danish pharma giant has also loaded up the evidence base to support the expected surge in prescriptions. Eligible Americans with a body-mass index above 35 – or above 30 with certain comorbidities – will pay just $50 a month out of pocket, while the government picks up about $245 net per patient. Some 3.8 million Medicare beneficiaries fall into that pool, and the pilot is scheduled to run through the end of 2027.
That policy tailwind arrives on the heels of a wave of clinical data presented at the American Diabetes Association’s scientific sessions in early June. The SELECT study showed semaglutide 2.4 mg cut overall mortality by 19% and major adverse cardiovascular events by 20%. In the FLOW trial, type-2 diabetes patients with chronic kidney disease saw a 20% reduction in all-cause mortality and an 18% drop in cardiovascular events. Oral semaglutide, meanwhile, lowered major heart events by 14% in the SOUL study. And early-stage pipeline candidate Zenagamtide (formerly Amycretin) delivered up to 14.6% weight loss after 36 weeks in phase 2, suggesting the product cycle extends well beyond the current GLP-1 generation.
Management is reinforcing its confidence with a buyback programme that has already retired approximately 0.9% of the share capital. Since February, Novo Nordisk has spent around 5.9 billion Danish kroner (roughly €790 million) on repurchases, acquiring more than 22 million B-shares under a total envelope of about €2 billion.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The stock has responded accordingly, rallying nearly 12% over the past thirty days. At Monday’s close of €42.35, it has climbed back above the 200-day moving average. Yet technical indicators flash caution: the relative strength index has climbed to 71.9, with a separate calculation putting it at 71.6 – firmly in overbought territory. Despite the recent bounce, the shares remain 31% below their 52-week high of €61.20 and still carry a year-to-date loss of roughly 5%.
The near-term path for the equity now depends heavily on how quickly the Medicare bridge program generates actual prescription volume. Jefferies analyst Michael Leuchten lifted his price target to 285 Danish kroner but maintained a “Hold” rating, citing a number of uncertainties for the remainder of the year. First monthly data from the program is expected to land around August, and that will give investors the clearest signal yet on whether the clinical and political stars have aligned for a sustained weight-loss drug adoption.
Ad
Novo Nordisk Stock: New Analysis - 30 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
